Management of Glomerulonephritis with Epithelial and Hyaline Casts
The presence of epithelial and hyaline casts in glomerulonephritis indicates tubular injury and proteinuria, requiring immediate supportive management focused on blood pressure control, proteinuria reduction, and edema management, while the specific immunosuppressive therapy depends entirely on the underlying glomerular disease type identified by kidney biopsy.
Initial Diagnostic Approach
The finding of epithelial and hyaline casts suggests active glomerular disease with tubular involvement. You must:
- Perform urinalysis with microscopy to evaluate for glomerular hematuria (red cell casts, acanthocytes) and quantify proteinuria 1
- Obtain kidney biopsy when feasible, as this is the gold standard for diagnosis and determines specific treatment 2
- Check autoimmune serologies (ANCA, ANA, anti-GBM antibodies, complement levels) 3
- Exclude infection before initiating any immunosuppression 3
Critical caveat: If the clinical presentation suggests rapidly progressive glomerulonephritis (RPGN) with positive ANCA serology or anti-GBM antibodies, do not wait for biopsy results to start immunosuppressive therapy 3. The biopsy should be obtained soon after treatment initiation when feasible.
Immediate Supportive Management (Universal for All GN Types)
These measures are at least as important as immunosuppression for long-term prognosis 4:
Blood Pressure Control
- Target aggressive BP reduction using RAS blockade (ACE inhibitors or ARBs) as first-line
- Add calcium channel blockers for stage 2 hypertension 5
Proteinuria Quantification and Goals
- Quantify proteinuria using protein-creatinine ratio (PCR) or 24-hour urine collection 1
- Target PCR <200 mg/g (<20 mg/mmol) in children 1
- Proteinuria reduction is a key therapeutic goal regardless of GN type
Edema Management
Loop diuretics are first-line 1:
- Use twice-daily dosing (preferred over once daily)
- Escalate dose until clinically significant diuresis or maximum effective dose reached
- Switch to bumetanide or torsemide if furosemide fails or oral bioavailability is questionable
Dietary sodium restriction: <2.0 g/day (<90 mmol/day) 1
For resistant edema, add sequential diuretics 1:
- Thiazide-like diuretics (any high-dose thiazide equally effective)
- Amiloride (counters hypokalemia, helps metabolic alkalosis)
- Spironolactone (but monitor for hyperkalemia, especially with RAS blockade)
- Acetazolamide as adjunct
Monitor for diuretic complications: hypokalemia, hyponatremia, volume depletion (especially pediatric/elderly), hyperkalemia with potassium-sparing agents, and impaired GFR 1
Disease-Specific Immunosuppression
The specific immunosuppressive regimen cannot be determined without knowing the histologic diagnosis from kidney biopsy 6, 7. Different GN types require completely different approaches:
If ANCA-Associated Vasculitis (AAV)
Induction therapy 3:
- Rituximab OR cyclophosphamide plus glucocorticoids
- Consider cyclophosphamide if severe GN (creatinine >4 mg/dL)
- Combination of two IV cyclophosphamide pulses with rituximab can be considered for severe disease
Maintenance therapy 3:
- Rituximab (preferred) OR azathioprine plus low-dose glucocorticoids
- Duration: minimum 18 months, up to 4 years
Plasma exchange: NOT routinely recommended for AAV alone, but use if AAV overlaps with anti-GBM antibody GN 3
If Infection-Related GN
- Antibiotics required for staphylococcus-associated GN, infective endocarditis-associated GN, and shunt nephritis 5
- Immunosuppression suggested only for crescentic IRGN or rapidly progressive course 5
- Therapy is predominantly supportive otherwise
If Immune Complex-Mediated MPGN
- Often refractory to nonspecific immunosuppression 8
- Consider C3 inhibition (pegcetacoplan) for refractory cases, though this remains investigational 8
Monitoring and Long-Term Care
All patients require structured long-term follow-up 4:
- Serial monitoring of serum creatinine, urinalysis, and blood pressure
- Particularly critical for crescentic GN or rapidly progressive GN 5
- Lifelong nephrological care determines prognosis 4
Monitor complement C3: If persistently low beyond 12 weeks, this is an atypical feature requiring kidney biopsy 5
Key Clinical Pitfalls
- Do not delay immunosuppression if RPGN with positive ANCA or anti-GBM antibodies—treat empirically while arranging biopsy 3
- Do not neglect supportive measures—they are prognostically equivalent to immunosuppression 4
- Do not use aggressive diuresis without sodium restriction—dietary compliance is essential 1
- Do not combine potassium-sparing diuretics with RAS blockade without close potassium monitoring 1
- Do not assume all GN requires immunosuppression—infection-related GN is primarily supportive 5